Berman McAleer’s AbbVie ABBV Stock Holding History

Berman McAleer’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$538K	Sell	2,138 -5	-0.2%	-$1.08K	0.06%	100
2026 Q1	$466K	Buy	2,143 +100	+5%	+$22.2K	0.06%	100
2025 Q4	$467K	Buy	2,043 +29	+1%	+$6.61K	0.06%	101
2025 Q3	$466K	Buy	+2,014	New	+$410K	0.07%	98

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Berman McAleer's ABBV Position: Q2 2026 in Review

Berman McAleer reduced its AbbVie (ABBV) stake by 0.23% in Q2 2026, selling an estimated $1.08K and leaving 2,138 shares worth $538K. The position accounts for 0.06% of the portfolio, ranked #100.

Berman McAleer first reported a position in ABBV in Q3 2025 and has held it in 4 quarters since. 4,188 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Berman McAleer held 2,138 shares of AbbVie worth $538K as of Q2 2026.
Berman McAleer sold 5 AbbVie shares in Q2 2026, an estimated $1.08K.
AbbVie made up 0.06% of Berman McAleer's portfolio in Q2 2026, its #100 holding.
Berman McAleer first reported a position in AbbVie in Q3 2025 and has held it in 4 quarters since.
4,188 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Berman McAleer's 13F filing for Q2 2026, filed 16 Jul 2026.